# Tiny Fat Bubbles That Deliver Drugs Directly to the Liver

> This patent describes special tiny fat bubbles, called lipid nanoparticles, designed to carry gene therapy drugs efficiently and specifically to liver cells for treating liver diseases.

- **Patent:** US 11464870
- **Original title:** Lipid nanoparticles for in-vivo drug delivery, and uses thereof
- **Owner:** Enhancedbio
- **Granted:** 2022
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, gene_editing, telecommunications

## What it does

This patent claims a specific type of lipid nanoparticle (LNP) designed for delivering drugs inside the body. The LNP is made from a precise mix of four main ingredients: an 'ionizable lipid' (which changes its charge depending on acidity), a 'phospholipid', 'cholesterol', and a 'lipid-PEG conjugate' (claim 1). These tiny particles are engineered to specifically target liver tissue, including liver cells (hepatocytes) and liver blood vessel lining cells (LSECs) (claims 7, 8, 9). They can encapsulate and deliver 'anionic drugs' or 'nucleic acids' like mRNA or siRNA (claim 10, 14), which are important for gene therapy. For example, these LNPs could carry an siRNA to the liver to silence a gene causing a specific liver disease.

## What it does NOT cover

- Does not cover lipid nanoparticles that lack any of the four specific components: an ionizable lipid, a phospholipid, cholesterol, or a lipid-PEG conjugate (claim 1).
- Does not cover lipid nanoparticles where the lipid-PEG conjugate is outside the range of 0.5 to 5 mol % (claim 1).
- Does not cover drug delivery methods using non-anionic drugs or drugs that are not nucleic acids (claim 10).
- Does not cover lipid nanoparticles that do not specifically target liver tissue or liver cells (claims 7, 8, 9).
- Does not cover lipid nanoparticles with an average diameter outside the range of 30 nm to 150 nm (claim 12).

## The clever bit

The clever part is the precise combination and ratios of the lipid components, especially the ionizable lipid and the small amount of lipid-PEG conjugate, which allows the nanoparticle to specifically target liver cells while efficiently encapsulating and releasing nucleic acid drugs. The specific pKa range of 6.0 to 7.0 (claim 6) is key, allowing the nanoparticle to be stable in the bloodstream but release its cargo once inside the slightly more acidic environment of a cell's endosome.

## Real-world examples

1. mRNA vaccines (like Pfizer-BioNTech and Moderna COVID-19 vaccines, which use LNPs for delivery)
2. Gene therapies for liver diseases (e.g., Alnylam's Onpattro for ATTR amyloidosis)
3. Experimental treatments for hepatitis B virus
4. Drug delivery systems for genetic disorders affecting the liver

## Why it matters

Targeting drugs directly to specific organs like the liver is a major challenge in medicine, especially for gene therapies. This patent offers a way to create lipid nanoparticles that are highly efficient and biocompatible, meaning they are less likely to cause harm. By specifically delivering nucleic acids to the liver, these nanoparticles could help treat serious liver conditions like ATTR amyloidosis, hypercholesterolemia, and hepatitis B virus infection (claim 16).

## Frequently asked questions

### What does Tiny Fat Bubbles That Deliver Drugs Directly to the Liver cover?

This patent describes special tiny fat bubbles, called lipid nanoparticles, designed to carry gene therapy drugs efficiently and specifically to liver cells for treating liver diseases.

### Who owns patent US 11464870?

Enhancedbio owns this patent, granted in 2022.

### When does this patent expire?

This patent is expected to expire on October 19, 2041, when the invention enters the public domain.

### What problem does this patent solve?

Targeting drugs directly to specific organs like the liver is a major challenge in medicine, especially for gene therapies. This patent offers a way to create lipid nanoparticles that are highly efficient and biocompatible, meaning they are less likely to cause harm. By specifically delivering nucleic acids to the liver, these nanoparticles could help treat serious liver conditions like ATTR amyloidosis, hypercholesterolemia, and hepatitis B virus infection (claim 16).

### What does this patent NOT cover?

Does not cover lipid nanoparticles that lack any of the four specific components: an ionizable lipid, a phospholipid, cholesterol, or a lipid-PEG conjugate (claim 1).

**Full plain-English explainer:** https://patentbrief.org/patent/us/11464870/lipid-nanoparticles-for-in-vivo-drug-delivery-and-uses-thereof

**Original patent:** https://patents.google.com/patent/US11464870

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells](https://patentbrief.org/patent/us/10307490/lipid-nanoparticle-compositions-for-antisense-oligonucleotides-delivery) — This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.
- [Tiny Bubbles for Delivering Medicine](https://patentbrief.org/patent/us/20250235403/compositions-and-methods-of-the-delivery-of-active-agents-including-nucleic-acid) — This patent describes tiny, bubble-like structures made of fats that can carry medicine, like genetic material, and release it effectively inside the body by changing their structure in slightly acidic environments.
- [How to Build Tiny Lipid Capsules to Deliver Genetic Medicines](https://patentbrief.org/patent/us/10155945/method-of-producing-lipid-nanoparticles-for-drug-delivery) — A precise method for creating small, stable lipid bubbles that safely carry genetic material like siRNA into cells for medical treatment.
- [Targeting Drugs to Specific Body Tissues Using ApoE3-Coated Nanoparticles](https://patentbrief.org/patent/us/20190307892/targeted-drug-delivery-and-therapeutic-methods-using-apo-e-modified-lipid-nanopa) — This patent describes a method to deliver drugs or diagnostic agents precisely to target cells or tissues, including the brain, by packaging them inside tiny fat particles (lipid nanoparticles) coated with a special protein called ApoE3.
- [Delivering Large Gene Editing Tools into Cells with Hybrid Virus-Lipid Packages](https://patentbrief.org/patent/us/12350368/delivery-of-large-payloads) — This patent describes a sophisticated delivery system that combines parts of a virus with a fat bubble (liposome) to efficiently transport large molecules, like CRISPR gene-editing components, into specific cells.
